Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Income Before Tax
Profit after all operating and non-operating items but before income tax.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$4.57M, compared with -$8.48M a year earlier. Trailing-twelve-month income before tax was -$19.58M.
Context
- Income before tax grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -$4.57M or moves back toward the trailing-twelve-month quarterly average of -$4.89M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (23.49M) USD
- Year-over-year change
- +30.9%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.49M) | +30.9% |
| FY2024 | 2024-12-31 | (33.97M) | -31.7% |
| FY2023 | 2023-12-31 | (25.79M) | -20.5% |
| FY2022 | 2022-12-31 | (21.4M) | -82.6% |
| FY2021 | 2021-12-31 | (11.72M) | — |
Income Before Tax vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's LTM Mar 2026 income before tax of -$19.58M is the 3rd highest of the 8 companies compared; the peer median is -$46.9M.
- Its year-over-year change of +41.2% is the 3rd highest of 8, against a peer median of +17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $62.49M | +132.0% | — | 50.5% | |
| LTM Mar 2026 | $15.5M | +122.2% | — | 28.3% | |
| LTM Mar 2026 | -$19.58M | +41.2% | — | — | |
| LTM Mar 2026 | -$21.76M | -35.5% | — | — | |
| LTM Mar 2026 | -$46.9M | +22.1% | — | 4088.8% | |
| LTM Mar 2026 | -$70.38M | +17.8% | — | 468.0% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$106.93M | -82.4% | — | 892.4% |
| LTM Mar 2026 | -$342.56M | -319.3% | — | 4571.1% | |
| Peer median (excluding CGTX) | -$46.9M | +17.8% | — | 680.2% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 235K | 0 | 0 | 0 |
| Gross Profit | 0 | (235K) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 18.57M | 30.32M | 37.2M | 41.68M | 37.19M |
| Selling, General & Admin | 10.03M | 13.23M | 13.53M | 12.29M | 10.61M |
| Operating Expenses | 28.6M | 43.32M | 50.72M | 53.97M | 47.8M |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| EBITDA | (10.73M) | (21.13M) | (25.51M) | (33.68M) | (23.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (28.6M) | (43.55M) | (50.72M) | (53.97M) | (47.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.45M | 22.22M | 24.81M | 0 | 0 |
| Interest Expense | 893K | 28K | 27K | 25K | 13K |
| Other Income / Expenses | 16.88M | 22.15M | 24.94M | 20M | 24.31M |
| Income Before Tax | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | (22.15M) | 0 | 0 | 0 |
| Net Income | (11.72M) | 757K | (25.79M) | (33.97M) | (23.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.74) | (0.86) | (0.85) | (0.32) |
| EPS (Diluted) | (0.73) | (0.74) | (0.86) | (0.85) | (0.32) |
| Weighted Avg Shares | 22.23M | 28.99M | 29.99M | 39.73M | 72.77M |
| Weighted Avg Shares (Diluted) | 22.23M | 28.99M | 30.03M | 39.73M | 72.77M |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.